



Correction

Correction: Martins et al. Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review. *Pharmaceuticals* 2022, *15*, 210

Ana M. Martins ^{1,*}, Ana L. Gomes ², Inês Vilas Boas ², Joana Marto ^{1,*} and Helena M. Ribeiro ¹

- Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003 Lisbon, Portugal; hribeiro@campus.ul.pt
- Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal; analucia199867@gmail.com (A.L.G.); inesvb97@gmail.com (I.V.B.)
- * Correspondence: amartins@farm-id.pt (A.M.M.); jmmarto@ff.ulisboa.pt (J.M.)

The authors would like to make the following corrections about the published paper [1]. The changes are as follows:

Missing Citation

In the original publication, refs. [2,3] was not cited. The citation has now been inserted in 4. The Skin Endocannabinoid System and the Use of Cannabinoids as a Potential Treatment for Skin Inflammatory Diseases, 4.1. The Skin Endocannabinoid System, Table 2 caption. Newly add references as [47,48] in the original paper, the order of some reference citation has been adjusted correspondingly.

"Table 2. The different classes of cannabinoids located in the skin, and some examples [15,37,47,48]."

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

References

- Martins, A.M.; Gomes, A.L.; Vilas Boas, I.; Marto, J.; Ribeiro, H.M. Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review. *Pharmaceuticals* 2022, 15, 210. [CrossRef]
- Muller, C.; Morales, P.; Reggio, P.H. Cannabinoid Ligands Targeting TRP Channels. Front. Mol. Neurosci. 2019, 11, 487. [CrossRef]
- 3. Mnekin, L.; Ripoll, L. Topical Use of Cannabis sativa L. Biochemicals. Cosmetics 2021, 8, 85.



Citation: Martins, A.M.; Gomes, A.L.; Boas, I.V.; Marto, J.; Ribeiro, H.M.
Correction: Martins et al.
Cannabis-Based Products for the
Treatment of Skin Inflammatory
Diseases: A Timely Review.
Pharmaceuticals 2022, 15, 210.
Pharmaceuticals 2022, 15, 849.
https://doi.org/10.3390/ph
15070849

Received: 23 May 2022 Accepted: 6 June 2022 Published: 11 July 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).